Still Hungry on Ozempic or Mounjaro: Causes and What to Check

Still feeling hungry on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) is common, and it rarely has a single cause. The US labels say these drugs decrease calorie intake, likely by affecting appetite^[1,2], but that’s an average against placebo: they don’t switch hunger off completely, or equally in everyone. Starting doses, protein, fiber, long gaps without food, sleep and stress all play a part. Here I go through what the labels and trials say, what you can check yourself and when to talk to your doctor. Any change to your dose or your medication is your prescriber’s decision.

A note on names: in the US, Ozempic and Mounjaro are approved for type 2 diabetes, and Wegovy and Zepbound are the same molecules approved for weight management. If what you notice is a pull toward sweets more than hunger, I cover it in sweet cravings on Ozempic or Mounjaro. If you’re not on a GLP-1 medication, the general causes of constant hunger are in always hungry: causes and what helps.

What the labels say about hunger

• Wegovy and Zepbound (US). Section 12.2 of both the Wegovy label and the Zepbound label says the drug decreases calorie intake, and the effects are likely mediated by affecting appetite^[1,2]. That’s as far as the US labels go.Dotted underline: a drug-label fact; hover over it to see the date it was checked.
• Wegovy (EU). The EU prescribing information is more specific: clinical studies show that semaglutide reduces energy intake, increases feelings of satiety, fullness and control of eating, and reduces feelings of hunger and the frequency and intensity of cravings. The figure: in a phase 1 trial, energy intake during an ad libitum meal (eating as much as they wanted) was 35% lower than with placebo after 20 weeks^[5].
• Mounjaro (EU). According to its EU prescribing information, tirzepatide reduces energy intake and appetite by increasing feelings of satiety and fullness and decreasing feelings of hunger; it also reduces the intensity of food cravings and preferences for high-sugar and high-fat foods^[6].

The 2025 joint advisory on nutrition and GLP-1 therapy, from four US medical and nutrition societies (I’ll call it “the advisory”), puts the range across studies at 16% to 39% less energy intake than with placebo, linked to changes in cravings, hunger and fullness^[10].

Three nuances. “Reduces” compares averages with placebo. The 35% was measured after 20 weeks of treatment^[5], not in the first week. And part of the early fullness may fade: the Zepbound label says tirzepatide delays gastric emptying, and the delay is largest after the first dose and diminishes over time^[2], while the EU Wegovy label notes that no clinically relevant effect on the rate of gastric emptying was observed with semaglutide 2.4 mg, probably due to a tolerance effect^[5]. No study I’ve found links that fading to hunger coming back, so treat it as a possibility, not an explanation. How these signals work is in the science of satiety.

Is Zepbound or Ozempic not working, or is it something else?

The large trials measured weight, not each person’s hunger, but weight shows how much the response varies.

• STEP 1. In the trial paper (summary), with 1,961 adults without diabetes, 86.4% of those on semaglutide 2.4 mg lost at least 5% of their weight in 68 weeks, compared with 31.5% on placebo^[7]. So 13.6% didn’t reach that 5%. The US Wegovy label, using a different analysis of the same trial, gives 83.5% vs. 31.1% on placebo^[1].
• SURMOUNT-1. In the trial paper (summary), with 2,539 adults without diabetes, 85%, 89% and 91% lost at least 5% on tirzepatide 5, 10 and 15 mg in 72 weeks, compared with 35% on placebo^[8]. Between 9% and 15% didn’t. Table 2 of the Zepbound label gives 85.1%, 88.9% and 90.9%, vs. 34.5% on placebo^[2].

The advisory notes that some people lose very little weight on these drugs and others lose 30% or more^[10]. Losing little isn’t the same as feeling hungry, but the spread is wide. The full figures are in how much weight people lose on GLP-1 medications.

The first weeks: starting doses, not maintenance doses

All four drugs start on a low dose that goes up gradually. According to the US labels, checked on October 5, 2026:

• Wegovy. It starts at 0.25 mg once weekly and goes up every 4 weeks (0.5, 1 and 1.7 mg) to reduce the risk of gastrointestinal side effects; from week 17, the maintenance dose for weight reduction in adults is 1.7 mg or 2.4 mg (2.4 mg recommended). A 7.2 mg dose also exists, but the label limits it to patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated: a criterion about weight, not hunger, that only the prescriber applies. If a dose isn’t tolerated during escalation, prescribers can consider delaying the next increase for 4 weeks^[1].
• Zepbound. It starts at 2.5 mg once weekly for 4 weeks, then 5 mg; the dose may go up in 2.5 mg steps after at least 4 weeks on the current dose. The maintenance doses for weight are 5, 10 or 15 mg. The label tells prescribers to consider treatment response and tolerability when selecting the maintenance dose, and a lower one if a maintenance dose isn’t tolerated^[2].
• Ozempic. It starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg; the maintenance dose is 0.5, 1 or 2 mg, based on blood sugar control, so its steps follow glucose, not appetite^[3].
• Mounjaro. It starts at 2.5 mg once weekly; if more blood sugar control is needed, the dose goes up in 2.5 mg steps after at least 4 weeks on the current dose, to a maximum of 15 mg in adults^[4].

Each dose also takes a few weeks to reach what the labels call “steady state”, when the drug level stops changing from week to week. For semaglutide, the Ozempic label says steady state is reached after 4 to 5 weeks of once-weekly dosing^[3]; for tirzepatide, the Zepbound label says after 4 weeks^[2].

I haven’t found studies that measure hunger week by week during the dose increases. What there is: in a post hoc analysis of SURMOUNT-1, the authors argue that 12 weeks may be too early to judge tirzepatide, because its escalation can take up to 20 weeks to reach the top dose. Among participants who took most of their doses, 18% hadn’t lost 5% by week 12, and 90% of them got there by week 72^[9].

These schedules are rules for prescribers, not a calendar to follow on your own. If you feel it isn’t working, don’t skip ahead, repeat or change doses yourself: bring it up with your prescriber, who decides whether anything changes.

Hunger, cravings and “food noise” aren’t the same thing

Before looking for causes, it helps to name what you’re feeling.

According to the advisory, several studies show that GLP-1 medications reduce cravings and food preoccupation, or “food noise”^[10]. If what you feel is cravings or noise more than physical hunger, eating more doesn’t always settle it. Noticing when it shows up (tiredness, stress, food in sight, many hours without eating) gives you more to work with. Food noise has its own guide: food noise: what it is and what GLP-1 drugs do.

One finding from Hill: trying to ban a specific food is linked to stronger cravings for that food^[15]. That’s not a reason to restrict more, but a reason not to turn food into a list of forbidden items.

What you can check yourself

Are you getting enough protein?

The advisory cites 0.8 g of protein per kilogram a day (about 0.36 g per pound) for the general population and notes that 1.2 to 1.6 g/kg (about 0.55 to 0.73 g/lb) has been proposed during active weight loss. Because it’s unclear which body weight to use with obesity, it also offers a fixed 80 to 120 g a day, and calls sufficient protein a priority^[10]. A 2015 review finds that protein raises fullness modestly^[13]. You can estimate your number with the protein calculator and go over it with your clinician, especially if you have kidney disease. How to get there with a small appetite is in protein and muscle on GLP-1 medications.

And enough fiber?

EFSA, the European Food Safety Authority, considers 25 g of fiber a day adequate for normal bowel function in adults^[11]. The National Academies recommend 25 g a day for women and 38 g for men up to age 50^[12]. To prevent constipation, the advisory suggests increasing fiber-rich foods gradually and getting enough fluids^[10]. The fiber calculator adds up your day, and the most filling foods lists the ones that combine fiber and protein.

Do you go many hours without eating?

The advisory describes a common pattern: with little interest in food, some people go several hours without eating. For some, that means falling short on nutrients. For others, waiting until they’re overly hungry can push them toward sugars and refined carbohydrates afterward. When hunger is low, it suggests small, frequent meals and, if that’s not enough, setting an alarm or reminder to eat^[10].

What to eat on GLP-1 medications has ideas by phase, the weekly menu planner helps you spread out meals, and filling snacks on GLP-1s has options for in between. If you’re eating very little overall, vitamins and minerals when you eat very little covers which nutrients to watch.

What’s on your plate?

In a 2019 NIH trial, 20 adults ate as much as they wanted from an ultra-processed diet for 2 weeks and an unprocessed diet for 2 weeks, with meals matched for calories, sugar, fat and fiber. On the ultra-processed diet they ate about 508 more calories a day^[18]. It was done without medication, on a hospital ward, but it suggests some foods fill you up less than the calories they deliver. If hunger tempts you to cut calories hard, do I have to count calories on Ozempic explains what the trials actually asked people to do.

How are your sleep and stress?

In a 2004 study with 12 healthy young men, two nights with 4 hours in bed raised hunger by 24% and ghrelin, the hormone that stimulates it, by 28%. Appetite for high-calorie, carbohydrate-rich foods rose by 33% to 45%^[17]. The advisory notes that poor sleep is associated with more hunger and weight gain, which might reduce some of the benefits of these drugs^[10]. I go deeper, stress included, in sleep, stress and appetite.

Has your weight stalled?

After months of weight loss, appetite can creep up as the body adapts, which I cover in the weight-loss plateau on Ozempic, Wegovy or Zepbound. More hunger in that phase doesn’t on its own mean the drug has stopped working. If you’ve already reached your goal, what maintenance tends to look like is in reaching your goal weight on a GLP-1.

The pen, storage and technique: ask your pharmacist

If you suspect the pen isn’t working, was stored badly (after a trip or a hot day, say) or you’re unsure of your technique, don’t troubleshoot it with forum advice: ask your pharmacist or care team. Each drug’s Instructions for Use explain how to use and store its pen^[1,2]. For trips, see disposing of pens and needles, and travelling.

With insulin or a sulfonylurea, “hunger” may be low blood sugar

If you have type 2 diabetes and also use insulin or a sulfonylurea (such as glipizide, glimepiride or glyburide), there’s another possibility. The Wegovy label warns that patients with diabetes taking it with insulin or an insulin secretagogue may have an increased risk of hypoglycemia, including severe hypoglycemia^[1]. The Zepbound label puts a number on it: in its trial of people with type 2 diabetes, low blood sugar occurred in 10.3% of people on Zepbound who also took a sulfonylurea, vs. 2.1% of those who didn’t^[2].

Both Medication Guides list hunger among the signs of low blood sugar, along with dizziness, sweating, shakiness, headache, confusion or drowsiness, irritability and a fast heartbeat^[1,2]. The Wegovy guide adds that you should talk to your healthcare provider about how to recognize and treat it^[1].

If the “hunger” comes on suddenly with any of these signs, follow the low-blood-sugar plan your doctor gave you and bring it up at your next visit. If you don’t have a plan, ask for one.

When to talk to your doctor

For adults, neither the Wegovy nor the Zepbound label sets a time frame for judging whether treatment works, and the 2025 advisory doesn’t give one either^[1,2,10]. So there’s no magic date: if you’ve been on a maintenance dose for months and your hunger hasn’t changed, it’s a good topic for your next appointment. According to MedlinePlus, increased appetite can have other causes, such as anxiety, some medicines (corticosteroids, among others), diabetes, hyperthyroidism or hypoglycemia, and it advises contacting your provider if the increase is unexplained and persistent^[19].

If food causes you distress, guilt or fear, or you often eat large amounts without being hungry, talk to your doctor. Eating disorders are serious mental health conditions, and they can be treated^[20]. The goal of treatment is to eat well with less hunger, not to eat as little as possible.

Frequently asked questions

Is it normal to be hungrier on 7.5 mg than on 5 mg?

I haven’t found studies that measure hunger at each step of the escalation, so I can’t tell you whether it’s typical. The Zepbound label says tirzepatide exposure increases in a dose-proportional manner, and also that, in its weight trials, most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time^[2]. One unproven explanation: if digestive discomfort was holding your appetite back, you notice hunger more once it eases. Changes in sleep, stress or schedule can also coincide. Note it for a few weeks and bring it up with your prescriber, who decides whether anything changes.

Does the first dose do nothing?

Starting doses are there mainly so your body can adjust, and they aren’t maintenance doses^[1,2]. Each dose also takes about 4 weeks (tirzepatide) or 4 to 5 weeks (semaglutide) to reach steady state^[2,3]. Noticing little effect on your appetite at first doesn’t mean the treatment won’t work.

Why does hunger come back in the last days before my shot?

No label or study I’ve found tracks hunger across the week; this rests on the drugs’ timing. Semaglutide reaches its maximum concentration 1 to 3 days after the dose, with an elimination half-life of about 1 week^[3]; for tirzepatide, the median time to peak is 24 hours (range 8 to 72 hours), and the half-life is about 5 to 6 days in people with overweight or obesity^[2]. Levels then fall until the next dose. Late-week hunger fits that, but it’s a hypothesis, and no data show it predicts a weaker response. The Zepbound label lets you change the injection day as long as the time between the two doses is at least 3 days (72 hours), and the Wegovy Medication Guide as long as your last dose was given 2 or more days before^[1,2]. That’s a label rule, not dosing advice. Ask your prescriber; see what you can check yourself.

If I’m still hungry, does it mean Zepbound isn’t working?

Not necessarily. The trials measured weight, not each person’s hunger, and in the SURMOUNT-1 analysis 9 in 10 people who hadn’t lost 5% by week 12 reached it later^[9]. If you’ve been on a maintenance dose for months with no change in hunger or weight, that’s a conversation for your prescriber, not a reason to change anything on your own.

Should I switch from Ozempic to Mounjaro, or from Wegovy to Zepbound?

That’s for your prescriber to decide. Ozempic is approved for type 2 diabetes, not for weight management^[3]. The head-to-head trial of tirzepatide and semaglutide in obesity, SURMOUNT-5, measured weight, not hunger; I summarize it in Ozempic vs Mounjaro. Mounjaro and Zepbound are the same molecule with different labels, as I explain in Mounjaro vs Zepbound. Both drugs are covered in depth in the semaglutide guide and the tirzepatide guide.

Do I just have to put up with the hunger?

No. Going hungry day after day isn’t the goal of treatment, and it can push you to eat worse later. Check your protein, the long gaps without food and your sleep, and if the hunger continues, bring it up with your doctor or a registered dietitian.